Akiram Therapeutics and ITM Isotope Technologies Munich (ITM) announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177 or 177Lu) to support the development of 177Lu-AKIR001 (AKIR001), a targeted antibody-radionuclide conjugate with first-in-class potential, currently in clinical testing for the treatment of CD44v6-expressing solid tumors. Under the terms of the agreement, ITM will provide its high-quality n.c.a. Lu-177 for use in Akiram’s ongoing clinical trial for AKIR001, the company’s lead radiopharmaceutical candidate. Lu-177 is one of the most widely used medical radioisotopes in targeted radionuclide therapy and serves as the active payload in AKIR001. AKIR001 is a targeted radiopharmaceutical drug candidate that combines the therapeutic radioisotope n.c.a. Lu-177 with a proprietary antibody targeting CD44v6, a cancer marker associated with several aggressive tumor types. Press release. 

Baylor College of Medicine announced that a new research agreement with United Therapeutics Corporation will provide up to $5 million a year for five years to establish the Baylor College of Medicine Center for Xenoliver Transplantation and Immunomodulation (XTI), dedicated to advancing scientific understanding of xenoliver transplantation. XTI’s efforts will place a particular emphasis on patient populations with high unmet needs who may face additional barriers to receiving a timely liver transplant, including patients with end-stage organ failure and patients whose immune systems have formed antibodies to foreign tissue. XTI will also explore immunomodulatory interventions, including mechanisms that may drive dendritic cells, which play an important role in adaptive immune response, to improve human tolerance to a xenoliver transplantation. Press release.

The Stein Institute for Research on Aging at the University of California San Diego will serve as the Central Laboratory and Biorepository for the XPRIZE Healthspan Competition, in which teams from around the world compete for $101 million in research funding to create innovative interventions that restore muscle, cognitive, and immune function in order to extend the human healthspan. Press release. 

Owkin announced a data collaboration with Kognitic to integrate Kognitic's clinical trial data into K Pro, Owkin's AI Scientist. The collaboration will initially focus on oncology and immunology and has the potential to expand into additional therapeutic areas and datasets over time. Kognitic structures global clinical trial signals into a normalized, decision-ready evidence layer for commercial, medical, and BD teams. These signals span trial registries, pipeline timelines, and competitive landscape data. Through this collaboration, Kognitic clinical data will be accessible directly within K Pro, giving decision-making teams a single source of data across fragmented feeds. Press release. 

Verified Clinical Trials (VCT) entered a new partnership with WindRose Health Investors to begin an exciting new chapter of growth. VCT's industry-recognized subject registry platform is designed to support patient safety, compliance, and data integrity from enrollment through study completion. VCT detects and helps prevent duplicate enrollment and other important protocol violations at the time of screening — issues that compromise research subject safety, affect data quality, create operational and regulatory challenges, and increase the risk of study failure. Press release. 

The COPD Foundation announced plans for an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting for chronic obstructive pulmonary disease (COPD). This meeting is modeled after the FDA’s PFDD public meetings. The meeting will enhance understanding of how living with COPD impacts daily life experiences; capture representative perspectives across the population on what matters most for improving their condition; and inform therapy development and regulatory decision-making with insights on current care and treatment benefit needs. Press release. 

The European Medicines Agency (EMA) has chosen TrialAssure’s ANONYMIZE platform as an official anonymization tool used within the agency. ANONYMIZE is designed to support the secure handling of sensitive information across an expansive scope of documents, datasets, and images. The platform combines AI-assisted detection with expert oversight to help organizations protect patient privacy and maintain the scientific utility of the clinical data and information itself. EMA will use ANONYMIZE to redact clinical documents such as dossiers submitted by market authorization holders to protect the identity and privacy of global clinical trial participants. Such documents will be posted to the public in accordance with transparency initiatives like EMA Policy 0043. Press release. 

NeuraLight announced that its platform will be deployed as part of the Healthy Brain Ageing (HeBA) study, a landmark European initiative advancing how brain function is measured and tracked across the aging population. The collaboration deploys NeuraLight’s precision brain function biomarkers in a population-scale program built to detect the earliest changes in the brain, up to a decade before symptoms appear. HeBA is one of the most ambitious brain-aging efforts in Europe: a four-country program designed to identify people at risk of developing Parkinson's disease early. Spanning Germany, Austria, Spain, and Luxembourg, the study focuses on adults aged 50-80 and has enrolled nearly 13,000 participants. Press release. 

ProAxsis announced progress in its expansion into the chronic obstructive pulmonary disease market through an ongoing clinical research study in collaboration with Imperial College London. The study builds on the company’s established position in bronchiectasis and alpha-1 antitrypsin deficiency, where its technology has already supported important clinical programs with global pharma. These include the phase 2 WILLOW study for Insmed and the use of ProAxsis’ ProteaseTag lab-based assays for biomarker analysis, which helped support the FDA approval of BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis and now a blockbuster drug. Press release.  

The National Organization for Rare Disorders announced three newly designated NORD Rare Disease Centers of Excellence, expanding the national network's clinical and research expertise across pediatric and adult medicine. With these additions, the network now includes 49 designated Rare Disease Centers of Excellence members across 28 states and the District of Columbia, with affiliations spanning more than 170 academic medical centers, research institutions, and children's hospitals nationwide. Press release.